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1Department of Pathology & Laboratory Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; 2Wisconsin National Primate Research Center,
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A number of publications have described the use of adeno-
associated virus (AAV) for the delivery of anti-HIV and anti-
simian immunodeficiency virus (SIV) monoclonal antibodies
(mAbs) to rhesus monkeys. Anti-drug antibodies (ADAs)
have been frequently observed, and long-term AAV-mediated
delivery has been inconsistent. Here, we investigated different
AAV vector strategies and delivery schemes to rhesus monkeys
using the rhesus monkey mAb 4L6. We compared 4L6 immu-
noglobulin G1 (IgG1) delivery using the AAV1 versus the
AAV8 serotype with a cytomegalovirus (CMV) promoter and
the use of a muscle-specific versus a liver-specific promoter.
Long-term expression levels of 4L6 IgG1 following AAV8-
mediated gene transfer were comparable to those following
AAV1-mediated gene transfer. AAV1-mediated gene transfer,
using a muscle-specific promoter, showed robust ADAs and
transiently low 4L6 IgG1 levels that ultimately declined to
below detectable levels. Intravenous AAV8-mediated gene
transfer, using a liver-specific promoter, also resulted in low
levels of delivered 4L6 IgG1, but those low levels were main-
tained in the absence of any detectable ADAs. Booster injec-
tions using AAV1-CMV allowed for increased 4L6 IgG1 serum
levels in animals that were primed with AAV8 but not with
AAV1. Our results suggest that liver-directed expression
may help to limit ADAs and that re-administration of AAV
of a different serotype can result in successful long-term deliv-
ery of an immunogenic antibody.
INTRODUCTION
The efficacy of passively administered anti-HIV broadly neutral-
izing antibodies (bnAbs) has been demonstrated in a number of
trials in monkeys and in humans.1–3 Whereas passive transfer is
a reasonable approach to prevent and treat HIV infection, it has
practical limitations for large-scale and long-term use. The
immense costs associated with monoclonal antibody (mAb) pro-
duction, the limited bioavailability following infusion, the need
for repeated infusions over a prolonged period, and adherence
will likely be problematic, especially in regions of the developing
world. Lifelong delivery following a single administration of the
adeno-associated virus (AAV) vector encoding the desired anti-
HIV bnAb is a promising alternative.4
Multiple preclinical studies in monkeys have shown that AAV-
delivered bnAbs and antibody-likemolecules can protect against acqui-
sition of immunodeficiency virus infection5–10 and are also capable of
controlling virus replication once infected.11 Nonetheless, the effective-
ness of the AAV-antibody approach has been hindered by the emer-
gence of unwanted immune responses following AAV administration.
These immune responses, including anti-drug antibodies (ADAs), limit
the bioavailability of AAV-delivered bnAbs and consequently reduce
or eliminate their antiviral effect.12–14 The degree of immunogenicity
is dependent on a variety of factors. Whereas autologous administered
“self” proteins may not be expected to elicit immune responses, they do
in hosts who have mutations or are missing the protein entirely.15
mAbs may be viewed as foreign/nonself, especially when the variable
domain regions are vastly diverged from the host germline and/or
when the constant regions are from a different species.12,16
In a previous study, we attempted to deliver the anti-simian immuno-
deficiency virus (SIV) antibody 4L6 immunoglobulin G1 (IgG1) to six
rhesus monkeys. Following AAV1-mediated gene transfer, all six
monkeys developed readily detectable ADAs that severely restricted
bioavailability of 4L6 IgG1 in serum in five of the six monkeys for
the 14 weeks of measurement.6 With the goal of comparing head to
head several vector strategies and delivery schemes, we designed
3-monkey pilot studies to investigate AAV-mediated delivery of the
4L6 IgG1 mAb. Here, we describe how liver-directed AAV-antibody
gene transfer can avoid the emergence of ADAs and that subsequent
intramuscular re-administration of AAV of a different serotype can
result in sustained high-level delivery of an immunogenic antibody.
RESULTS
Antibody Delivery Using AAV1-CMV as Compared to AAV8-CMV
In our previous monkey experiment, we utilized a bicistronic single-
stranded AAV (ssAAV) vector construct with the capsid of the AAV1
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serotype.6 Following intramuscular inoculation, the serum levels of
the AAV-delivered 4L6 IgG1 mAb were at 47–150 mg/mL at peak
(weeks 3–4) but then precipitously dropped to 0–7 mg/mL by week
14 in five of the six monkeys, whereas only one monkey maintained
a reasonable 4L6 IgG1 concentration of 38 mg/mL at week 14. 4L6-
IgG1-specific ADAs were detected in all six monkeys.6,12 Here, we
describe 3-monkey pilot experiments using 4L6 IgG1 as our model
antibody. We redesigned our initial bicistronic ssAAV vector encod-
ing the 4L6 mAb by modifying the 30 UTR: the woodchuck hepatitis
virus post-transcriptional regulatory element (WPRE) was removed
(due to safety concerns),17 and microRNA-binding sites (miRNAbs)
were inserted into all constructs (Figure 1). The selectedmiRNAbs are
complementary in sequence to the microRNAs of miR-142-3p18–20
and miR-126-3p,21 which are both highly expressed in antigen-pre-
senting cells (APCs). The idea behind including these two miRNAbs
is that inadvertently AAV-transduced APCs may no longer express
the 4L6 IgG1 mAb, which could avoid or blunt adaptive immune re-
sponses, including ADAs.
In our first group, we enrolled three AAV1-negative monkeys. Each
monkey was inoculated intramuscularly with 0.25 1013 AAV1 par-
ticles harboring the redesigned 4L6 IgG1 expression cassette with a
cytomegalovirus (CMV) promoter.22 Serum levels of the AAV-deliv-
ered mAb were measured by ELISA using SIVmac239 gp120 as cap-
ture antigen and recombinant (r)4L6 IgG1 as standard. Following
AAV administration, levels of 4L6 IgG1 peaked at 52–108 mg/mL
within 4–6 weeks but declined considerably thereafter. Whereas
two animals had a nadir concentration of 4 and 9 mg/mL at week
16, rhesus monkey r12010 had undetectable 4L6 IgG1 at week 10
throughout week 78 (Figure 2A). The decline in mAb levels was asso-
ciated with the emergence of ADAs in all three animals (Figure 2B).
ADAs in r12010 were strong and persisted for the duration of the
study. The other two animals exhibited moderate ADAs that gradu-
ally declined to baseline by week 50; the gradual decline in ADAs
was associated with a gradual increase in 4L6 IgG1 levels between
weeks 16 and 50 (Figures 2A and 2B).
We next assessed the possibility of boosting mAb levels in these
AAV1 recipients. The three animals that received AAV1-CMV into
the quadriceps muscle were injected with the same AAV1-CMV
construct to the deltoid and biceps muscle at week 50. At the time
of the boost, mAb levels were at 0, 18, and 49 mg/mL. Minimal or
no boosting effects in 4L6 IgG1 levels were observed in the weeks
following AAV1-CMV re-administration. At week 78, the study
endpoint, mAb levels were at 0, 51, and 62 mg/mL, respectively (Fig-
ure 2A). Interestingly, no anamnestic ADA response was observed
following the AAV1 booster inoculation (Figure 2B).
In our second group, three AAV1/AAV8 double-negative monkeys
were injected intramuscularly with 0.25  1013 AAV8 particles
harboring the same expression cassette as in group 1. Following the
AAV8-CMV inoculation, serum levels of 4L6 IgG1 were in the range
of 35–71 mg/mL at peak (within 6–10 weeks). Two of the three mon-
keys showed just a slight decrease in mAb levels following the peak;
only rhesus monkey r13022 had a 10-fold drop between weeks 6
and 12. At week 12, the nadir concentrations were at 6, 23, and
58 mg/mL. By week 50, levels of 4L6 IgG1 gradually rose to 74, 48,
and 121 mg/mL, respectively (Figure 3A). ADA responses were
detected in all three animals. From the time of the peak at weeks
8–10, ADAs gradually decreased to baseline in all three animals by
week 50 (Figure 3B). Interestingly, 4L6 IgG1 levels did not appear
to be affected by the emergence of ADAs in r13098, the monkey
with the strongest initial ADA response in the group of three (Figures
3A and 3B).
As in group 1, we tested the possibility of boosting mAb levels in
serum. The three AAV8-CMV recipients were injected intramuscu-
larly with AAV1-CMV at week 50. In contrast to group 1, group 2 dis-
played a boosting effect in 4L6 IgG1 levels within the first 12 weeks
following the booster inoculation. At week 62, mAb levels were at
438, 207, and 333 mg/mL, respectively, i.e., an average 4.3-fold in-
crease in 4L6 IgG1 levels. However, these boosted mAb levels subse-
quently normalized to 221, 119, and 168 mg/mL, respectively, by week
Figure 1. AAV Vector Design
The AAV expression vector contains the following: a CMV promoter, amuscle-specific desmin promoter, or a liver-specific TBG promoter; a SV40 intron; a SV40 polyA signal;
constant regions of IgG1 heavy and light chains from rhesus (rh) monkey, a rhesus signal peptide (SP), and the rh variable domains (VH and VL) of the 4L6 sequences that
originate from recombinant anti-SIV Fab sequences derived from the bone marrow of SIV-infected rhesus monkeys. The expression cassette is flanked by AAV serotype 2
inverted terminal repeats (ITR). In this bicistronic single-stranded AAV (ssAAV) vector, both heavy and light chains of IgG are expressed from one open reading frame using a
F2A “self-processing” peptide from foot-and-mouth disease virus. The furin cleavage sequence “RKRR” for the cellular protease furin is added for removal of amino acids that
were left on the heavy chain C terminus following F2A self-processing. The peptide linker “SGSG” is added for improved furin enzyme-mediated cleavage. The 30 UTR
contains multiple binding sites for conserved endogenous microRNAs (miRNAs) that are specifically expressed in antigen-presenting cells (miRNAbs). This is designed to
render the mAb transcripts sensitive to translational inhibition by the miRNAs expressed in antigen-presenting cells. Abbreviations are as follows: mAb, monoclonal antibody;
CMV, cytomegalovirus; TBG, thyroxine-binding globulin; SV40, simian virus 40; VH, variable heavy domain; CH, constant heavy domain; H, hinge; VL, variable light domain;
CL, constant light domain; pA, polyadenylation signal; and rh, of rhesus monkey origin.
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78 (Figure 3A). As observed in group 1, the monkeys in group 2 also
did not elicit an anamnestic ADA response following the AAV1-
CMV booster inoculation (Figure 3B).
Muscle-Directed AAV-Antibody Delivery
Intramuscular injection of AAV leads to local transduction of myo-
cytes. However, a fraction of the intramuscularly injected AAV may
also disseminate to other sites23,24 and/or transduce other cell types,
including cells of the immune system. This could facilitate the trig-
gering of unwanted immune responses, such as ADAs. Since the ubiq-
uitous CMV promoter drives transgene expression in most cell
types,22 we explored the possibility of containing transgene expres-
sion to the muscle by using a muscle-specific promoter. In our third
group, we enrolled three AAV1-negative monkeys. Each monkey was
injected intramuscularly with 0.25  1013 AAV1 particles harboring
the 4L6 IgG1 expression cassette with a desmin promoter.25 Serum
levels of the 4L6 IgG1 mAb peaked to 1–7 mg/mL between weeks 3
and 8 and subsequently dropped precipitously to undetectable levels
in all three animals by week 16 (Figure 4A). The decline in mAb levels
was associated with robust ADAs that persisted through week 36, the
study endpoint (Figure 4B).
Figure 2. AAV1 Prime/AAV1 Boost-Mediated Antibody Delivery Using the
CMV Promoter
(A) Levels of the monoclonal antibody (mAb) 4L6 IgG1 in serum following intra-
muscular (i.m.) AAV1 administrations. Intramuscular AAV1 boost had little or no
effect on 4L6 IgG1 levels in AAV1-seropositive animals. (B) Anti-drug antibody (ADA)
responses following i.m. AAV1 administration. Inclusion of microRNA-binding site
(miRNAb) sequences into the rAAV genome did not limit ADA responses. No
anamnestic humoral response was observed following AAV1 boost.
Figure 3. AAV8 Prime/AAV1 Boost-Mediated Antibody Delivery Using the
CMV Promoter
(A) AAV8-mediated gene transfer resulted in stable 4L6 IgG1 levels in three of three
monkeys. An AAV1 boost markedly increased the levels of 4L6 IgG1 in AAV1
seropositive animals. (B) Anti-drug antibody (ADA) responses following intramus-
cular (i.m.) AAV8 prime and subsequent AAV1 boost administrations. AAV8-medi-
ated gene transfer resulted in moderate ADA responses that resolved by week 50.
No anamnestic humoral response was observed following AAV1 boost.
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Liver-Directed AAV-Antibody Delivery
It has been suggested that liver-directed transgene expression is able
to induce tolerance toward the transgene product and prevent the
emergence of immune responses, including ADAs.26–34 We thus de-
signed a 4L6 IgG1 expression cassette with a liver-specific promoter
to investigate whether liver-directed AAV-antibody delivery could
avoid unwanted ADAs. Three AAV1/AAV8 double-negative mon-
keys were injected intravenously with 0.25  1013 AAV8 particles
harboring the 4L6 IgG1 expression cassette with a thyroxine-bind-
ing globulin (TBG) promoter.35–38 Following AAV8-TBG inocula-
tion, serum levels of 4L6 IgG1 were detectable but relatively low
in all three animals, ranging from 0.3 to 2.3 mg/mL through week
14 (Figure 5A). Notably, none of the three monkeys developed
any detectable ADA responses (Figure 5B). At week 14, we conduct-
ed an AAV booster inoculation. The three AAV8-TBG recipients
were intramuscularly injected with 0.25  1013 AAV1 particles
harboring the 4L6 IgG1 expression cassette with a CMV promoter.
Within 6 weeks following the boost, serum levels of delivered 4L6
IgG1 peaked to 186–302 mg/mL at week 20. In the subsequent weeks,
mAb levels declined to 6, 120, and 145 mg/mL (Figure 5A). ADA
responses were detected as early as 4 weeks following the boost
(week 18), but these ADAs were weak and had a downward trend
by week 28 (Figure 5B).
Figure 4. AAV1-Mediated Antibody Delivery Using the Muscle-Specific
Desmin Promoter
(A) AAV1-mediated gene transfer under a muscle-specific promoter resulted in low
levels of 4L6 IgG1 that were undetectable by week 16. (B) Anti-drug antibody (ADA)
responses following intramuscular (i.m.) AAV1 administration. AAV-mediated gene
transfer under a muscle-specific promoter resulted in robust ADA responses.
Figure 5. AAV8 Prime/AAV1 Boost-Mediated Antibody Delivery Using the
Liver-Specific TBG Promoter (Prime) and the CMV Promoter (Boost)
(A) AAV8-mediated gene transfer under a liver-specific TBG promoter resulted in
low levels of 4L6 IgG1. An AAV1-CMV boost strongly elevated the levels of 4L6 IgG1
in serum in AAV8-seropositive animals. (B) Anti-drug antibody (ADA) responses
following intravenous (i.v.) AAV8 prime inoculation using the TBG promoter and
subsequent intramuscular (i.m.) AAV1 boost administration using the CMV pro-
moter. AAV8-mediated gene transfer under a liver-specific TBG promoter avoided
ADA responses. An AAV1-CMV boost elicited moderate ADAs that appeared to
decrease by week 28.
www.moleculartherapy.org
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Group Comparison
Two of the three monkeys that received AAV1-CMVmaintained 4L6
IgG1 levels throughout the duration of the study (Figure 2A). In the
AAV8-CMV group, the 4L6 IgG1 mAb was delivered successfully to
all three monkeys (Figure 3A). Following AAV administration, the
serum levels of 4L6 IgG1 rose to a peak and subsequently declined.
Whereas the decline in mAb levels was followed by a rebound in
five of the six animals, rhesus monkey r12010 had undetectable
4L6 IgG1 by week 10 throughout the end of the study (Figures 2A
and 3A). Cumulative mAb levels in both groups, AAV1-CMV and
AAV8-CMV, were comparable and not significantly different. In
contrast, delivery of 4L6 IgG1 to the third group that received
AAV1-desmin was poor and significantly lower than the other two
groups that utilized the CMV promoter (Figure 6A).
The animals that received AAV1-CMV (Figure 2), AAV8-CMV (Fig-
ure 3), and AAV8-TBG (Figure 5) were boosted with AAV1-CMV at
either week 50 or week 14. Serum levels of AAV-delivered 4L6 IgG1
were followed for 14 weeks from the time of the AAV1-CMV boost
and compared to the levels at the time of the boost. Animals that
received AAV1-CMV showed no increased 4L6 IgG1 levels following
the AAV1-CMV boost. Animals that received either AAV8-CMV or
AAV8-TBG showed significantly increased 4L6 IgG1 levels following
the AAV1-CMV boost (Figure 6B).
DISCUSSION
Following administration of AAV1-CMV-4L6 or AAV8-CMV-4L6
by the intramuscular route (Figures 2 and 3), there was an early
and strong ADA response to the delivered 4L6mAb. This greatly sup-
pressed the early 4L6 IgG1 concentrations in serum. However, the
ADAs gradually declined in five of the six monkeys, eventually reach-
ing levels below the limit of detection beyond week 36. This gradual
decline in ADA levels corresponded to a gradual increase from trough
levels in the 4L6 IgG1 concentration between weeks 16 and 50. This is
a pattern that we have occasionally, but rarely, seen in our AAV de-
livery experiments using eight other mAbs, all constant domain-
rhesusized (C-rhesusized) versions of human anti-HIV mAbs.11,12
Most commonly, the early appearance of strong ADAs has driven
the delivered mAb levels to undetectable or marginally detectable
levels. It is worth noting that the assay for ADA measures free but
not bound anti-antibodies; thus, the absence of detection of ADAs
may simply mean that their levels are not saturating, i.e., not in excess
of the delivered antibody levels.
What are some of the factors that may influence the appearance of
ADAs to therapeutic antibodies? Martinez-Navio et al.12 have shown
that ADAs predominantly target the variable domains of an antibody
and that the magnitude of the ADA response to AAV-delivered mAbs
correlates directly with the distance of the variable domains of the
antibody from germline. This is a problem because the potent anti-
HIV bnAbs that one would like to deliver by AAV to the host typically
have unusually long variable domains, are hypermutated, and/or
harbor unusual structures.2,39,40 The host origin of the delivered
mAb may also be a factor. The 4L6 mAb used here, as well as the
Figure 6. Statistical Analysis of AAV-Delivered 4L6 IgG1 Levels in Serum
(A) Levels of AAV-delivered 4L6 IgG1 in serum were compared in the three
groups enrolled in the study: AAV1-CMV, AAV8-CMV, and AAV1-desmin. The
area under the curve (AUC) of 4L6 IgG1 levels through week 36 was calculated,
and the three groups were analyzed by one-way ANOVA Tukey’s multiple
comparisons test; *p < 0.05; **p < 0.01. (B) The effect of an AAV1-CMV boost
was compared in the three groups enrolled in the study: AAV1-CMV prime/
AAV1-CMV boost (week 50), AAV8-CMV prime/AAV1-CMV boost (week 50),
and AAV8-TBG prime/AAV1-CMV boost (week 14). Levels of 4L6 IgG1 following
AAV booster inoculation (weeks 50–64 and 14–28) were averaged and
compared to the levels at the time of the boost (week 50 or 14). The boosting
effect is expressed as net-increase difference in 4L6 IgG1 as compared to the
time of the boost. The values were analyzed by one-way ANOVA Tukey’s mul-
tiple comparisons test; *p < 0.05. Monkey r12010 in the AAV1-CMV/AAV1-CMV
group was excluded from the analysis due to undetectable levels of 4L6 IgG1 at
the time and following the time of the boost.
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5L7 mAb in our previous publication,6 are of rhesus monkey
origin.5,41,42 They also have very long heavy chain complemen-
tarity-determining region 3 (H-CDR3) regions in their variable do-
mains.12 Whereas the eight anti-HIV mAbs that we have used for
AAV delivery have been rhesusized in their constant regions, their
variable domains still originate from the human germline. Whereas
the 4L6 mAb and the 5L7 mAb have still quite consistently elicited
ADAs following intramuscular AAV administration, far greater
consistency of long-term delivery has been achieved with these
rhesus monkey mAbs than with the eight C-rhesusized human
anti-HIV mAbs. Cell types that may be expressing the mAb may
also be a factor, dependent upon the route of administration, AAV
dose, promoter used, and AAV serotype: muscle cells, lymphocytes,
APCs, liver cells.
Will ADAs be a problem when human anti-HIV mAbs are delivered
to humans via AAV? A recently published human trial of AAV to
deliver the human anti-HIV mAb PG9 revealed readily detectable
ADAs in ten of thirteen volunteers in four dosage groups and zero
measureable delivery of the PG9 mAb.13,43 Further human phase 1
trials are certainly warranted using different vector designs and
different mAbs to expand the database of knowledge regarding
AAV delivery of anti-HIV mAbs to people and how consistently
ADAs appear to be a problem in people. But, in the meantime, mon-
key models can be used to understand the ADA problem better and to
examine ways by which the appearance of ADAs may be circum-
vented. The concentrations of mAbs needed to protect against the
acquisition of infection are likely to be considerably less than the con-
centrations needed to control virus replication in an already-infected
individual. Given the remarkable case of the functional cure of the
Miami monkey,11,44,45 further testing in both monkeys and people
appears warranted.
Previous studies have suggested that a low titer of pre-existing anti-
AAV8 antibodies (%1:160) does not influence the take of AAV8
following intramuscular administration.24 We investigated whether
levels of 4L6 IgG1 in serum could be boosted in monkeys that had
previously received AAV1-4L6 by a subsequent second intramuscular
administration of AAV1-4L6. Little or no boosting of 4L6 IgG1 levels
was observed. However, a second administration of AAV1-4L6 to
monkeys that had previously received AAV8-4L6 resulted in signifi-
cant boosting in the levels of the delivered 4L6 mAb. At least two
factors may be contributing to this boosting effect: the tolerizing
potential of AAV8 and the lack of major cross-reactivity between
AAV8 and AAV1 serotypes.
We have identified in our pilot monkey studies two strategies that
may help to overcome the problems of ADA and inconsistency of de-
livery: liver targeting and use of prime and boost. Liver-targeted
expression has been previously shown to have a tolerogenic effect
toward the AAV-delivered transgene product.26–34 Furthermore,
AAV8 has been shown to transduce APCs poorly, as compared to
AAV1,46 and to express well in liver.35–38 Consistent with this, our
results show no ADA to the 4L6 mAb when the AAV8 vector was
administered intravenously using a liver-specific TBG promoter for
expression despite the presence of readily detectable 4L6 IgG1 levels
in serum for the 14 weeks of measurement. Boosting with the AAV1-
CMV vector given intramuscularly showed a tremendous increase in
4L6 IgG1 levels that persisted at high levels for the 14 weeks of follow-
up in at least two of the three monkeys. The boosting was also accom-
panied by the emergence of ADAs. Further work will be needed to
examine the optimal conditions of the tolerizing liver-directed
AAV8 prime, the timing of the AAV1 boost, and the dose of the
AAV1 boost for their effects on the emergence and persistence of
ADAs and the ability to achieve long-term persistence of the delivered
mAb at reasonable levels.
MATERIALS AND METHODS
rAAV Vector Constructs
The 4L6 mAb variable domain sequences (VH [variable heavy]; VL
[variable light]) originate from the recombinant anti-SIV macaque
antibody-binding fragment (Fab) “346-16h” that derived from the
bone marrow of a SIV-infected rhesus monkey following Phage
library selection.5,41,42 The coding sequence of the full-length 4L6
IgG1 was constructed by fusing the variable heavy domain to the con-
stant heavy domains of rhesus IgG1 (based on NCBI: AAF14058 and
AAQ57555) and by fusing the variable light domain to the rhesus
kappa constant light domain (based on NCBI: AAD02577). A bicis-
tronic DNA sequence was then designed in silico, codon optimized
for rhesus monkeys, and gene synthesized (GenScript) as described
previously.47 The synthesized DNA fragment was subsequently
cloned into select ssAAV vector plasmids that contained a ubiquitous
CMV promoter, a muscle-specific desmin promoter, or a liver-
specific TBG promoter. All three ssAAV vector plasmids contained
a simian virus 40 (SV40) intron, miRNAbs as described previ-
ously,18–21 a SV40 polyA site, and the inverted terminal repeats
(ITRs) of the AAV2 serotype.
rAAVs
Production of rAAV particles was accomplished as described previ-
ously.48 In short, HEK293 cells were transfected with a select rAAV
vector plasmid and two helper plasmids to allow generation of infec-
tious AAV particles. rAAV vector genomes were encapsidated with
either the AAV1 or the AAV8 serotype capsid as indicated. After
harvesting transfected cells and cell culture supernatant, rAAV was
purified by three sequential CsCl centrifugation steps. Vector genome
number was assessed by real-time PCR, and the purity of the
preparation was verified by electron microscopy and silver-stained
SDS-PAGE.
Rhesus Macaques and AAV Delivery
The twelve animals used in our studies were Indian-origin rhesus ma-
caques (Macaca mulatta), housed at the Wisconsin National Primate
Research Center. They were cared for in accordance with the guide-
lines of the Weatherall Report under a protocol approved by the
University of Wisconsin Graduate School Animal Care and Use
Committee. Animals were tested negative for the presence of anti-
bodies to the AAV1 and the AAV8 capsids prior to AAV inoculations
www.moleculartherapy.org
Molecular Therapy: Methods & Clinical Development Vol. 16 March 2020 99
with the respective serotype. At the time of AAV prime inoculations,
the average age of the animals was 2.8 years (ranging from 1.6 to 4.6),
and the average weight was 4.0 kg (ranging from 2.4 to 7.4). A total of
six females and six males were enrolled in the study. The twelve
enrolled animals were separated into four groups of three. Nine of
the twelve animals received rAAVs by intramuscular inoculation
(AAV1-CMV, AAV8-CMV, and AAV1-desmin): 0.25  1013 vector
genomes per kg; four 0.5 mL injections per animal, two injections per
quadriceps muscle. Three of the 12 animals received rAAV by intra-
venous injection (AAV8-TBG): 0.25  1013 vector genomes per kg;
one 2 mL injection into the saphenous vein. Where indicated (week
14 or 50), nine of the twelve animals received intramuscular
AAV1-CMV booster inoculations: 0.25  1013 vector genomes per
kg; four 0.5 mL injections per animal. Two injections per quadriceps
muscle were performed. When intramuscular prime inoculations
were conducted on the quadriceps muscles, then booster inoculations
were conducted on the left and right deltoid and biceps muscles (four
0.5 mL injections per animal).
In Vivo mAb Quantification
HEK293T cells (ATCC) were expanded and then transfected with a
rAAV vector plasmid encoding the 4L6 IgG1 mAb. Complete D10
cell culture medium was replaced with serum-free DMEM medium,
18 h after transfection (Gibco). The antibody-containing medium
was harvested 90 h after transfection, precleared by centrifugation,
and filtered through a 0.22-mm pore-size membrane (Nalgene).
The 4L6 IgG1 was then affinity purified using protein A Sepharose
4 Fast Flow (GE Healthcare), concentrated and desalted, followed
by protein quantification with a Nanodrop spectrometer (Thermo
Fisher Scientific). To measure the concentration of 4L6 IgG1 in vivo,
we performed a SIVmac239 gp120 (Immune Tech)/anti-rhesus IgG-
horseradish peroxidase (HRP) ELISA (Southern Biotech) as previ-
ously described.6 Absorbance at 450 nm was compared to a serial
dilution of purifiedmAb produced in HEK293T cells, and the amount
of antibody in serum was determined based on the mAb standard
curve.
ADA Responses
Humoral responses to the AAV-delivered 4L6 IgG1 mAb were
measured by an antibody capture ELISA, as previously described.6,12
Plates were coated with purified 4L6 IgG1. After coating and blocking,
the plates were incubated with antisera from the AAV-immunized
monkeys. For detection, a HRP-conjugated anti-human lambda
light-chain antibody was used (Southern Biotech). This secondary
antibody did not cross-react with the coated mAb on the plates, since
4L6 IgG1 harbors a kappa light chain.
Statistical Analysis
All analyses were performed in Prism 6 (GraphPad). Comparisons
between two groups were performed using the unpaired two-tailed
t test with Welch’s correction. Comparisons among three groups
were performed using the one-way ANOVA Tukey’s multiple com-
parison test. All values are expressed as mean. p values of <0.05 (*)
and <0.01 (**) were considered significant.
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